Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Renal Cell Carcinoma
share announcement

Advances in Renal Cell Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 1368

Special Issue Editors

Prof. Dr. Philipp Ivanyi

E-Mail Website
Guest Editor
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany
Interests: real world analysis; urogenital cancers; sarcoma; head and neck cancers; renal cell carcinoma
Dr. Hendrik Eggers

E-Mail Website
Guest Editor
Department of Hematology and Oncology, Städtisches Klinikum Braunschweig, Celler Street 38, 308114 Braunschweig, Germany
Interests: lung cancer; renal cell carcinoma; real world analysis; risk factors

Special Issue Information

Dear Colleagues,

Medical treatment of renal cell carcinoma has experienced groundbreaking improvements over the last few decades. Evolving from an unselected immunotherapy with interferons and a type of treatment that only benefits very few patients, a broad range of highly effective therapies are available nowadays, including targeted therapies and immunotherapy. Treatment for this malignancy has demonstrated unparallel improvements in survival for patients who are deemed to be incurable. With the advances in medical treatment, an improved understanding of the diverse biological causes of the diseases and the multimodal care of RCC patients with individualized local and medical treatment sequencings represent the future scientific challenges.

Following these dramatic changes, there is still an urgent need to understand the advantages and characteristics of our current treatment strategies in different settings and populations. Therefore, this Special Issue will highlight all aspects of state-of-the-art therapy, including but not limited to special patient populations, prognostic or predictive markers and real-world application experiences.

We welcome all studies who share our fascination for this topic and help to understand how we can treat patients in the most effective manner possible.

Prof. Dr. Philipp Ivanyi
Dr. Hendrik Eggers
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • treatment
  • metastatic
  • prediction
  • medical treatment
  • immunotherapy
  • multimodal therapy
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 4024 KiB  
Article
Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma
by Sophie Carina Kunte, Adrien Holzgreve, Marcus Unterrainer, Josef Zahner, Hans Peter Schmid, Magdalena Schöll, Iulia Blajan, Gabriel T. Sheikh, Dirk Mehrens, Jozefina Casuscelli, Alexander J. Tamalunas, Rudolf A. Werner, Christian G. Stief, Michael Staehler and Lena M. Unterrainer
Cancers 2025, 17(11), 1736; https://doi.org/10.3390/cancers17111736 - 22 May 2025
Viewed by 145
Abstract
Background/Objectives: Early treatment assessment in metastatic renal cell carcinoma (mRCC) remains challenging due to the limited accuracy of current imaging methods. Given prostate-specific membrane antigen (PSMA) overexpression in mRCC, PSMA PET is a promising approach. Despite numerous studies on PSMA imaging in [...] Read more.
Background/Objectives: Early treatment assessment in metastatic renal cell carcinoma (mRCC) remains challenging due to the limited accuracy of current imaging methods. Given prostate-specific membrane antigen (PSMA) overexpression in mRCC, PSMA PET is a promising approach. Despite numerous studies on PSMA imaging in mRCC, data on PSMA uptake changes during systemic therapy are scarce. We analyzed PSMA uptake on PET after treatment initiation in mRCC patients. Methods: A retrospective single-center analysis of mRCC patients who underwent [18F]PSMA-1007 PET/CT before (PET1) and at a mean of 9.5 weeks after (PET2) starting systemic therapy was conducted. PSMA uptake in metastatic lesions was compared by region and RCC subtype. Uptake differences between PET1 and PET2 were analyzed using an unpaired t-test. Results: This study included 25 patients (mean age 65.2 ± 14.7 years; 20 male) with mRCC. A total of 113 (PET1) and 48 (PET2) metastases were assessed. Lymph node metastases showed stable PSMA uptake (median SUVmax) after treatment (7.8 vs. 7.7, p = 0.77), while uptake by bone (6.4 vs. 12.4, p = 0.03) and lung metastases (4.5 vs. 8.1, p = 0.004) increased significantly. SUV stability in lymph nodes was independent of RCC subtype (ccRCC: p = 0.48, pRCC: p > 0.99). Bone (6.6 vs. 15.9, p = 0.008) and lung metastases (4.8 vs. 8.1, p = 0.02) had higher PSMA uptake in ccRCC, unlike pRCC (bone: 6.2 vs. 6.0, p = 0.86). Conclusions: Alterations of PSMA-radioligand uptake are seen in bone and pulmonary metastases but not in lymph node metastases after initiation of systemic treatment in patients with mRCC. ccRCC has a higher PSMA uptake than other RCC subtypes. Full article
(This article belongs to the Special Issue Advances in Renal Cell Carcinoma)
►▼ Show Figures

Figure 1

11 pages, 1558 KiB  
Article
Endovascular Downstaging: A New Method for Managing Renal Cell Carcinoma Tumor Thrombus Invading the Inferior Vena Cava Above the Hepatic Veins (Level III) or into the Heart (Level IV)
by John A. Libertino, Malik Ahmed, Thomas Piemonte and Jason Gee
Cancers 2025, 17(2), 264; https://doi.org/10.3390/cancers17020264 - 15 Jan 2025
Viewed by 955
Abstract
Background: Renal cell carcinoma tends to invade venous structures, frequently extending beyond the inferior vena cava and into the heart itself, such as into the right atrium or right ventricle. Resection of tumor burden, particularly tumor thrombus, often requires cardiopulmonary bypass (CPB) and [...] Read more.
Background: Renal cell carcinoma tends to invade venous structures, frequently extending beyond the inferior vena cava and into the heart itself, such as into the right atrium or right ventricle. Resection of tumor burden, particularly tumor thrombus, often requires cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA), which is not feasible for all patients. Methods: Described in this study is a novel, minimally invasive endovascular approach involving endovascular thrombectomy as a viable approach in these select patients. Results: There were no surgical complications, shorter operating times, less blood loss and an average length of stay of 5.5 days in the four patients undergoing this procedure. Conclusions: We demonstrate that this technique can eliminate the need for cardiac bypass and deep hypothermic cardiac arrest and its associated risks, thereby making surgery safer and more accessible for patients with advanced kidney cancers with an inferior vena cava tumor thrombus. Furthermore, it allows for this life-saving surgery to be carried out in medical centers or hospitals where cardiac surgery is unavailable, or when cardiopulmonary bypass is medically contraindicated. Full article
(This article belongs to the Special Issue Advances in Renal Cell Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop